Download
img description

your ccure api by Lebsa and Selectchemie CAS-RN: 917389-32-3

Letermovir,
antiviral agent

Letermovir (CAS-RN 917389-32-3) is an antiviral agent approved in 2017 by US FDA to be used in prophylaxis of cytomegalovirus (CMV) infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant (HSCT).

Designated an orphan drug by FDA for prevention of CMV viremia and disease in at-risk populations.

img description

Letermovir EU figures

  • Trade name PREVYMIS
  • Annual sales 2021 156 M
    (+53%)
  • Annual API Kg 2021 210 Kg
    (+45%)
  • FDF IR Tablet & concentrate for solution for infusion 240, 480 mg
  • Indications Antiviral to prevent illness caused by CMV
  • Product Patent Expiry 17.04.2029
  • Data Protection & Market exclusivity 10.1.2028 (Orphan Drug Exclusivity)

Ask our specialist

Let us cure together

*Required fields